Nephromag (Buffered Phosphate Solution | Mertiatide)

Nephromag provides phosphate supplementation for conditions where phosphate balance is disrupted.

• Hypophosphatemia: restores serum phosphate levels in patients with low phosphate.
• Renal replacement therapy: supplies phosphate during dialysis to maintain electrolyte homeostasis.
• Metabolic acidosis correction: contributes buffering capacity to assist in pH regulation during critical care.

• The buffered phosphate solution delivers inorganic phosphate ions that participate in cellular energy metabolism, nucleic acid synthesis, and acid‑base buffering. Intravenous administration rapidly increases extracellular phosphate, supporting ATP production and helping to correct acid‑base disturbances by acting as a physiological buffer.

Nephromag may be associated with a range of adverse reactions.

Common Side Effects

• Hyperphosphatemia: elevated serum phosphate levels.
• Hypocalcemia: reduced calcium concentrations secondary to phosphate binding.
• Infusion site irritation: redness or discomfort at the injection site.
• Nausea: mild gastrointestinal upset.
• Headache: transient cranial discomfort.
• Flushing: temporary warmth or redness of the skin.

Serious or Rare Side Effects

• Metastatic calcification: calcium‑phosphate deposition in soft tissues.
• Cardiac arrhythmia: rhythm disturbances linked to electrolyte shifts.
• Severe allergic reaction: anaphylaxis or hypersensitivity.
• Renal failure exacerbation: worsening kidney function in susceptible patients.
• Hemodynamic instability: sudden blood pressure changes during infusion.
• Seizures: neurologic events related to electrolyte imbalance.

Nephromag should be used with careful clinical monitoring.

• Serum phosphate monitoring: check levels before and during therapy.
• Calcium balance: assess calcium status to avoid hypocalcemia.
• Renal function assessment: evaluate kidney performance prior to infusion.
• Hyperphosphatemia avoidance: do not administer to patients with already high phosphate.
• Infusion rate control: administer slowly to reduce risk of cardiovascular effects.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Nephromag can interact with other agents that affect electrolyte balance.

Major Interactions (Avoid)

• Calcium supplements: may precipitate calcium‑phosphate complexes.
• Antacids containing aluminum or magnesium: can interfere with phosphate absorption.
• Vitamin D analogues: potentiate hyperphosphatemia risk.

Moderate Interactions (Monitor Closely)

• Loop diuretics: increase renal phosphate loss, requiring dose adjustment.
• ACE inhibitors: may affect renal handling of phosphate.
• Bisphosphonates: combined effect on bone mineral metabolism.
• Parathyroid hormone analogues: alter calcium‑phosphate dynamics.